Expertise in
4
conditions

Eli Rosenbaum

Petah Tiqwa, M, IL 
Expertise in
4
conditions
Petah Tiqwa, M, IL 

Overview

Eli Rosenbaum practices practicing medicine in Petah Tiqwa, Israel.

Mr. Rosenbaum is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Chromophobe Renal Cell Carcinoma, Prostate Cancer, Renal Cell Carcinoma (RCC), Urothelial Cancer, and Prostatectomy.

He is actively involved in clinical research, co-authoring 48 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Petah Tiqwa, M, Israel
Other Locations
Petach Tikvah, Israel
Tel Aviv, TA, Israel
Ramat Gan, TA, Israel
Ramat Aviv, TA, Israel

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2026
Intervention Type: Drug
Study Phase: Phase 3
A Pilot Study on Endothelial Function and Cardiovascular Biomarkers in Prostate Cancer (PCa) Patients, With Pre-existing Cardiovascular Disease, Treated With Degarelix vs. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
A Pilot Study on Endothelial Function and Cardiovascular Biomarkers in Prostate Cancer (PCa) Patients, With Pre-existing Cardiovascular Disease, Treated With Degarelix vs. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
Enrollment Status: Completed
Publish Date: June 12, 2019
Intervention Type: Device, Drug
Study Phase: Phase 4
View 1 Less Clinical Trial

48 Total Publications

Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer.
Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer.
Journal: The New England journal of medicine
Published: July 22, 2026

Frequently Asked Questions about Eli Rosenbaum

Is Eli Rosenbaum a top-rated expert for Chromophobe Renal Cell Carcinoma?

MediFind is an objective health platform that identifies experts based on real-world data. Eli Rosenbaum is classified as an Distinguished expert for Chromophobe Renal Cell Carcinoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Eli Rosenbaum participate in research or clinical trials?

Yes. Eli Rosenbaum has published 48 articles and abstracts on conditions like Chromophobe Renal Cell Carcinoma. You can view a list of Eli Rosenbaum's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Rosenbaum's expertise for a condition
ConditionClose
    View All 7 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile